T1	intervention 29 60	anastrozole plus tegafur-uracil
T2	ethinicity 352 360	Japanese
T3	eligibility 361 424	women with ER-positive, HER2-negative, T2,N0-1,M0 breast cancer
T4	control 714 742	anastrozole (as above) alone
T6	outcome-Measure 869 930	proportion of patients with best overall response of CR or PR
T7	total-participants 1127 1129	57
T8	intervention-participants 1170 1172	29
T9	control-participants 1190 1192	28
T11	iv-bin-abs 1369 1374	39.3%
T12	cv-bin-percent 1398 1403	14.3%
T13	outcome 1493 1508	tumor shrinkage
T14	iv-cont-mean 1536 1540	31.0
T15	cv-cont-mean 1545 1550	14.2%
T16	outcome 1582 1606	Grade ≥ 3 adverse events
T17	iv-bin-percent 1668 1672	17.2
T18	cv-bin-percent 1677 1679	0%
T5	outcome 1365 1367	RR
